PhoreMost is at the forefront of drug discovery, utilizing its proprietary SITESEEKER® technology to expand the druggable space, particularly in oncology and Targeted Protein Degradation (TPD). The SITESEEKER platform employs genetically engineered mini proteins, known as PROTEINi, to identify and characterize protein-protein interactions (PPIs) that are often implicated in diseases like cancer. By integrating advanced techniques such as next-generation sequencing, functional genomics, and AI-assisted computational biology, PhoreMost aims to unlock previously undruggable targets, thereby accelerating the drug discovery process.

In addition to SITESEEKER, PhoreMost has introduced the GlueSEEKER platform, which focuses on the discovery of novel molecular glue degraders (MGDs). This platform enhances the ability to systematically design and evaluate new PPIs, addressing the challenges associated with MGD discovery. GlueSEEKER allows researchers to modify E3 ligase-protein of interest interfaces using MG-PROTEINi, facilitating the screening of vast chemical spaces to induce target protein degradation. Together, these technologies position PhoreMost as a leader in innovative therapeutic development, with a strong pipeline of programs aimed at tackling complex diseases through collaboration with industry partners.

United Kingdom

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

PhoreMost

Company Details